Literature DB >> 27432009

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Veronika Buxhofer-Ausch1,2, Bettina Gisslinger1, Martin Schalling1, Andreas Gleiss3, Ana-Iris Schiefer4, Leonhard Müllauer4, Jürgen Thiele5, Robert Kralovics6, Heinz Gisslinger1.   

Abstract

Entities:  

Keywords:  essential thrombocythaemia; myeloproliferative neoplasms; prefibrotic primary myelofibrosis; thrombosis; white blood cell count

Mesh：

Year:  2016        PMID： 27432009     DOI： 10.1111/bjh.14202

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

Review 2.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

3.  Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.

Authors:  Stefan Schmidt; Dimitri Daniliants; Elisabeth Hiller; Eberhard Gunsilius; Dominik Wolf; Clemens Feistritzer
Journal:  Blood Adv       Date:  2021-09-28

Review 4.  Prefibrotic myelofibrosis: treatment algorithm 2018.

Authors:  Guido Finazzi; Alessandro M Vannucchi; Tiziano Barbui
Journal:  Blood Cancer J       Date:  2018-11-07       Impact factor: 11.037

5.  JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing.

Authors:  Etienne Mahe; Kasper Mønsted Pedersen; Yunus Çolak; Stig Egil Bojesen; Tarah Lynch; Gary Sinclair; Faisal Khan; Meer-Taher Shabani-Rad
Journal:  J Clin Pathol       Date:  2018-12-04       Impact factor: 3.411

6.  Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.

Authors:  Novella Pugliese; Claudia Giordano; Davide Nappi; Luigiana Luciano; Claudio Cerchione; Mario Annunziata; Beniamino Casale; Elena Crisà; Maria Rosaria Villa; Luca Pezzullo; Maria Iovine; Marco Picardi; Francesco Grimaldi; Fabrizio Pane; Vincenzo Martinelli
Journal:  Cancer Med       Date:  2019-04-17       Impact factor: 4.452

7.  Austrian recommendations for the management of essential thrombocythemia.

Authors:  Veronika Buxhofer-Ausch; Sonja Heibl; Thamer Sliwa; Christine Beham-Schmid; Dominik Wolf; Klaus Geissler; Maria Theresa Krauth; Peter Krippl; Andreas Petzer; Albert Wölfler; Thomas Melchardt; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2020-11-19       Impact factor: 1.704

Review 8.  The new WHO classification for essential thrombocythemia calls for revision of available evidences.

Authors:  Tiziano Barbui; Jürgen Thiele; Alberto Ferrari; Alessandro M Vannucchi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2020-02-25       Impact factor: 11.037
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.